Literature DB >> 6240359

Hydralazine and lupus nephritis.

B U Ihle, J A Whitworth, J P Dowling, P Kincaid-Smith.   

Abstract

Renal involvement is uncommon in the hydralazine induced systemic lupus erythematosus syndrome. Six women with hypertension are described who developed an immune complex glomerulonephritis after taking 50-300 mg hydralazine daily for 6 months to 7 years. Associated features were anemia (100%), hypocomplementemia (50%), a positive antinuclear antibody test (100%) and antibodies to double-stranded DNA (66%). All patients were slow acetylators and four had HLA-DR 4 genotype. Renal function deteriorated in all cases. Cessation of hydralazine combined with immunosuppressive therapy resulted in amelioration of the disease. It is likely that the patients had a hydralazine induced lupus glomerulonephritis, or alternatively had an unmasking of an inherent tendency to idiopathic lupus nephritis by hydralazine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6240359

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  11 in total

Review 1.  Drug-induced glomerular disease: immune-mediated injury.

Authors:  Jonathan J Hogan; Glen S Markowitz; Jai Radhakrishnan
Journal:  Clin J Am Soc Nephrol       Date:  2015-06-19       Impact factor: 8.237

Review 2.  A Spotlight on Drug-Induced Vasculitis.

Authors:  Kinanah Yaseen; Alana Nevares; Hiromichi Tamaki
Journal:  Curr Rheumatol Rep       Date:  2022-09-21       Impact factor: 4.686

3.  Pharmacogenomics Informs Cardiovascular Pharmacotherapy.

Authors:  Mariana Babayeva; Brigitte Azzi; Zvi G Loewy
Journal:  Methods Mol Biol       Date:  2022

Review 4.  Drug-induced lupus.

Authors:  E J Price; P J Venables
Journal:  Drug Saf       Date:  1995-04       Impact factor: 5.606

5.  Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity.

Authors:  Samih H Nasr; Vivette D D'Agati; Hye-Ran Park; Paul L Sterman; Juan D Goyzueta; Robert M Dressler; Shawn M Hazlett; Robert N Pursell; Christopher Caputo; Glen S Markowitz
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-20       Impact factor: 8.237

Review 6.  Genotype-Guided Hydralazine Therapy.

Authors:  Kimberly S Collins; Anthony L J Raviele; Amanda L Elchynski; Alexander M Woodcock; Yang Zhao; Rhonda M Cooper-DeHoff; Michael T Eadon
Journal:  Am J Nephrol       Date:  2020-09-14       Impact factor: 3.754

7.  Outcomes of hydralazine induced renal vasculitis.

Authors:  Homa Timlin; Jason E Liebowitz; Khusleen Jaggi; Duvuru Geetha
Journal:  Eur J Rheumatol       Date:  2017-12-07

8.  Hydralazine-induced vasculitis presenting with ocular manifestations.

Authors:  Vivian S Hawn; Thomas A Vo; David Flomenbaum; Richard P Gibralter
Journal:  Am J Ophthalmol Case Rep       Date:  2022-04-10

Review 9.  The role of medications and their management in acute kidney injury.

Authors:  Bradford L McDaniel; Michael L Bentley
Journal:  Integr Pharm Res Pract       Date:  2015-05-18

Review 10.  Hydralazine-Induced ANCA Associated Vasculitis (AAV) Presenting with Pulmonary-Renal Syndrome (PRS): A Case Report with Literature Review.

Authors:  Karim Doughem; Ayman Battisha; Omar Sheikh; Lakshmi Konduru; Bader Madoukh; Mohammed Al-Sadawi; Shakil Shaikh
Journal:  Curr Cardiol Rev       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.